Tirzepatide
GLP-1 Agonists and Body Composition: What the Trial Data Shows
How tirzepatide and semaglutide affect fat vs. lean mass, what SURMOUNT-1 and STEP-1 show on body composition, why protein intake and resistance training change outcomes, and how to monitor body comp during GLP-1 therapy.
Informational only. Not medical advice. Consult a licensed healthcare provider before starting, changing, or stopping any protocol.
GLP-1 agonists and body composition: beyond the scale
GLP-1 receptor agonists (semaglutide, tirzepatide) produce weight loss primarily through appetite suppression, delayed gastric emptying, and reduced food reward signaling. The scale number drops — but what is actually being lost matters for long-term outcomes and muscle function.
Body composition refers to the ratio of fat mass to lean mass (muscle, bone, water). Two people can have the same body weight with dramatically different body compositions. For active users running GLP-1s as a body-recomposition tool — not just a weight loss drug — understanding this distinction changes how you structure training, protein intake, and monitoring.
What the trial data shows on lean mass
The SURMOUNT-1 trial (tirzepatide) and STEP-1 trial (semaglutide) both showed significant total weight loss. The body composition breakdown:
| Drug | Total weight loss | Estimated fat loss | Estimated lean mass loss |
|---|---|---|---|
| Tirzepatide 15 mg (SURMOUNT-1) | ~20.9% body weight | ~70–75% of loss | ~25–30% of loss |
| Semaglutide 2.4 mg (STEP-1) | ~14.9% body weight | ~70–75% of loss | ~25–30% of loss |
| Diet alone (typical) | ~5–10% body weight | ~60–70% of loss | ~30–40% of loss |
GLP-1 drugs compare favorably to diet-alone on lean mass preservation — but roughly 25–30% of the weight lost is still lean mass, not fat. At 20 lbs lost, that's approximately 5 lbs of muscle-containing lean tissue.
Why protein and resistance training change the calculus
Lean mass loss during caloric deficit is driven by two factors: inadequate protein intake and absence of mechanical stimulus (resistance training). GLP-1 drugs reduce appetite, which often reduces protein intake as a side effect — people eat less of everything, including protein.
Research on resistance training during GLP-1 therapy is limited, but the physiology is well established: progressive resistance training is the strongest signal for muscle protein synthesis. Users who combine GLP-1 therapy with consistent resistance training and high-protein intake (~0.7–1.0g protein per lb of goal body weight) substantially improve lean mass outcomes compared to users who don't.
Tirzepatide vs. semaglutide for body composition
Tirzepatide's dual GIP/GLP-1 mechanism may confer specific body composition advantages beyond greater total weight loss. GIP receptor activation has documented effects on adipose tissue metabolism — the GIP receptor is expressed in fat cells, and activation appears to shift the body toward fat oxidation. Early research suggests tirzepatide may have a slightly more favorable fat-to-lean-mass loss ratio compared to semaglutide, though head-to-head body composition data is limited.
The practical difference for a body-recomposition goal: tirzepatide achieves higher total weight loss (more fat removed) with a comparable lean mass preservation profile, making it the stronger tool for users whose primary goal is body composition versus metabolic health alone.
Monitoring body composition during GLP-1 therapy
Scale weight alone is an incomplete metric during GLP-1 therapy. Better markers:
- DEXA scan: Gold standard. Shows fat mass, lean mass, and bone density. Recommended at baseline and every 3–6 months during active weight loss phase.
- Bioelectrical impedance (InBody, Withings scale): Less accurate than DEXA but convenient for tracking trends. Consistent conditions matter (time of day, hydration state).
- Strength metrics: Are your lifts going up or holding? Declining performance on compound movements (squat, deadlift) alongside weight loss is a signal of lean mass loss.
- Waist-to-hip ratio: Simple, free, and predictive of visceral fat (the metabolically harmful kind). Tracks change in fat distribution independently of scale.
Stacking GLP-1s with peptides for body composition
Users with active body recomposition goals sometimes stack GLP-1 agonists with peptides that have complementary effects:
- CJC-1295/Ipamorelin: GH secretagogues that stimulate endogenous GH release. GH is anabolic for lean tissue and promotes fat oxidation — a mechanistically complementary goal for users trying to preserve muscle during GLP-1-driven fat loss.
- BPC-157: Injury/recovery support. GLP-1-induced appetite suppression can reduce protein intake and recovery; BPC-157's tissue repair mechanisms may support maintenance of training intensity.
Stack protocol design is your prescribing provider's domain. My Pep Calc tracks each compound independently — dose logs, schedules, half-life curves — so your provider has a complete picture of what you're running.
Tracking your protocol
A body composition-focused GLP-1 protocol has moving parts: weekly GLP-1 injections, dose escalation steps, possible peptide stack, injection site rotation, and periodic DEXA benchmarks. My Pep Calc logs all of it in one place — use the reconstitution calculator for each vial setup and the half-life chart to see active concentrations across your full protocol week.
Frequently asked questions
- Do GLP-1 drugs cause muscle loss?
- Yes, some lean mass loss occurs during GLP-1-driven weight loss — approximately 25–30% of total weight lost is lean mass rather than fat, based on SURMOUNT-1 and STEP-1 trial data. This is comparable to (and slightly better than) diet-alone weight loss. Adequate protein intake and consistent resistance training significantly reduce lean mass loss.
- Is tirzepatide better than semaglutide for body composition?
- Tirzepatide achieves higher total weight loss (up to ~21% vs. ~15% for semaglutide) and may have a slightly more favorable fat-to-lean-mass ratio due to GIP receptor activity on adipose tissue. Head-to-head body composition data is limited. Your prescribing provider can advise on which is appropriate for your specific goals.
- How much protein should I eat while on semaglutide or tirzepatide?
- GLP-1 drugs reduce appetite, which can inadvertently reduce protein intake. Many practitioners and dietitians recommend prioritizing protein at ~0.7–1.0g per lb of goal body weight during GLP-1 therapy. This is a general nutritional principle, not a medical prescription — discuss your specific targets with your provider.
- Can I stack CJC-1295/Ipamorelin with tirzepatide?
- CJC-1295/Ipamorelin (GH secretagogues) and tirzepatide (GLP-1/GIP agonist) work through entirely different mechanisms and are sometimes combined by users with body recomposition goals. Protocol design is your prescribing provider's call. My Pep Calc tracks both compounds independently so you have a complete dose log to share with your provider.
- How do I track body composition changes during a GLP-1 protocol?
- Scale weight alone is insufficient. DEXA scan is the gold standard (baseline + every 3–6 months). Bioelectrical impedance (InBody, Withings) is useful for trends between DEXA appointments. Track strength metrics in your training log as a proxy for lean mass. My Pep Calc tracks the drug side of the protocol; pair it with consistent body comp measurements.
Sources
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216.
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002.
- Rubino DM, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA. 2021;325(14):1414-1425.
Stop doing this math by hand.
My Pep Calc runs reconstitution, dose tracking, site rotation, and half-life curves for your whole stack — not just one compound.
See the Founders offer →